ClinicalTrials.gg
CompletedNCT04718103SWIFT-2Updated Nov 29, 2024Results posted

A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

A Phase 3 interventional study of GSK3511294 and Placebo in Asthma, sponsored by GlaxoSmithKline. Completed at 129 sites in 11 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2024-11-29.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
397
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing depemokimab in Asthma — 3 open to participants now, 3 under way, 3 of them phase 3. depemokimab · Asthma.

Enrollment
4th of 10
397 · median 273
Started
2021
with 3 others
Phase 3
7 of 10
3 open now
Registered
2nd of 10
by date
Lead sponsor
10 of 10
GlaxoSmithKline

Among the 10 studies testing depemokimab in Asthma, this one is the 4th largest by enrollment, is one of 4 that started in 2021, is one of 7 in phase 3, and was the 2nd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 10 studies testing depemokimab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About depemokimab

depemokimab: first FDA approval 2025 (EXDENSUR), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing depemokimab in Asthma, or all of them as a file.
02

Study summary

This study will assess the efficacy and safety of GSK3511294 (Depemokimab) as an adjunctive therapy in participants with severe uncontrolled asthma with an eosinophilic phenotype.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
  • Eosinophilic phenotype
  • Exacerbations
  • GSK3511294 (Depemokimab)
  • Placebo
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion criteria for study:

  • Adults and adolescents greater than or equal to (>=)12 years of age, at the time of signing the /assent.
  • Participants must have a documented physician diagnosis of asthma for >=2 years that meets the National Heart, Lung, and Blood Institute guidelines (NHLBI) or Global Initiative for Asthma (GINA) guidelines and

    1. Eosinophilic phenotype: participants who have, or with high likelihood of having, asthma with an eosinophilic phenotype as per randomization criteria, and
    2. Exacerbation history: participants who have previously confirmed history of >=2 exacerbations requiring treatment with systemic (CS) (Intramuscular [IM], Intravenous [IV], or oral), in the 12 months prior to Visit 1, despite the use of medium to high-dose ICS. For participants receiving maintenance CS, the CS treatment for the exacerbations must have been a two-fold dose increase or greater.
  • Persistent airflow obstruction as indicated by (i) For participants >=18 years of age at Visit 1, a pre-bronchodilator less than (\<)80 percent (%) predicted National Health and Nutrition Examination Survey (NHANES III) recorded at Visit 1.

(ii) For participants 12-17 years of age at Visit 1: A pre-bronchodilator FEV1 \<90% predicted (NHANES III) recorded at Visit 1 or FEV1: Forced Vital Capacity (FVC) ratio \<0.8 recorded at Visit 1.

  • A well-documented requirement for regular treatment with medium to high dose ICS (in the 12 months prior to Visit 1 with or without maintenance OCS). The maintenance ICS dose must be >=440 micrograms fluticasone propionate (FP) hydrofluoroalkane product (HFA) daily, or clinically comparable (GINA, 2020). Participants who are treated with medium dose ICS will also need to be treated with LABA to qualify for inclusion.
  • Current treatment with at least one additional controller medication, besides ICS, for at least 3 months (for example [e.g.], LABA, LAMA, leukotriene receptor antagonist [LTRA], or theophylline).

Key inclusion criteria for randomization:

  • An elevated peripheral blood eosinophil count of >=300 cells per microliter demonstrated in the past 12 months prior to Visit 1 that is related to asthma or an elevated peripheral blood eosinophil count of >=150 cells per microliter at Screening Visit 1 that is related to asthma.
  • Evidence of airway reversibility or responsiveness as documented by either:

    (i) Airway reversibility (FEV1>=12% and 200 milliliter [mL]) demonstrated at Visit 1 or Visit 2 using the Maximum Post Bronchodilator Procedure or (ii) Airway reversibility (FEV1>=12% and 200 mL) documented in the 24 months prior to Visit 2 (randomization visit) or (iii) Airway hyper-responsiveness (methacholine: Provocative concentration causing a 20% fall in FEV1 [PC20] of \<8 milligrams per milliliter (mg/mL), histamine: Provocative dose that decreases FEV1 by 20% [PD20] of \<7.8 micromoles, mannitol: decrease in FEV1 as per the labelled product instructions) documented in the 24 months prior to Visit 2 (randomization visit).

Key exclusion criteria for study:

  • Presence of a known pre-existing, lung condition other than asthma. This includes (but is not limited to) current infection, bronchiectasis, pulmonary fibrosis, bronchopulmonary aspergillosis, or diagnoses of emphysema or chronic bronchitis ( other than asthma) or a history of lung cancer.
  • Participants with other conditions that could lead to elevated eosinophils such as hyper-eosinophilic syndromes including (but not limited to) Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly known as Churg-Strauss Syndrome) or Eosinophilic Esophagitis.
  • A current or previous history of cancer in remission for less than 12 months prior to screening (Participants that had localized carcinoma of the skin which was resected for cure will not be excluded).
  • Cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice.
  • Participants who have known, pre-existing, clinically significant cardiac, endocrine, , metabolic, neurological, renal, gastrointestinal, hepatic, hematological or any other system abnormalities that are uncontrolled with standard treatment.
  • Participants with current diagnosis of vasculitis. Participants with high clinical suspicion of vasculitis at screening will be evaluated and current vasculitis must be excluded prior to enrolment.
  • Participants who have received mepolizumab (Nucala), reslizumab (Cinqair/Cinqaero), or benralizumab (Fasenra) within 12 months prior to Visit 1 or who have a previous documented failure with Anti-Interleukin-5/Anti-Interleukin-5 receptor (anti-IL-5/5R) therapy.
  • Participants who have received omalizumab (Xolair) or dupilumab (Dupixent) within 130 days prior to Visit 1.
  • Participants who have received any monoclonal antibody (mAb) within 5 half-lives of Visit 1.
  • Previously participated in any study with mepolizumab, reslizumab, or benralizumab and received study intervention (including placebo) within 12 months prior to Visit 1.
  • interval using Fridericia's formula (QTcF) >=450 milliseconds (msec) or QTcF >=480 msec for participants with Bundle Branch Block at screening Visit 1.
  • Current smokers or former smokers with a smoking history of >=10 pack years (number of pack years = [number of cigarettes per day/ 20] multiplied by number of years smoked). A former smoker is defined as a participant who quit smoking at least 6 months prior to Visit 1.
  • Participants with allergy/intolerance to the of GSK3511294 or any mAb or biologic.

Key exclusion criteria for randomization:

  • QTcF >= 450 msec or QTcF >=480 msec for participants with Bundle Branch Block, at randomization Visit 2 are excluded. Participants are excluded if an abnormal (ECG) finding from the 12-lead ECG conducted at Screening Visit 1 is considered to be clinically significant and would impact the participant's participation during the study, based on the evaluation of the Investigator.
  • Participants with a clinically significant asthma exacerbation in the 7 days prior to randomization should have their randomization visit delayed until the investigator considers the participant's asthma to be stable.
  • Any changes in the dose or regimen of Baseline ICS and/or additional controller medication (except for treatment of an exacerbation) during the run-in period.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
397 participants (actual)

Study arms

  • Experimental
    GSK3511294

    Participants received a 100 milligram (mg) dose of GSK3511294 subcutaneous (SC) injection once every 26 weeks (week 0 and week 26). Participants were to be maintained on their existing baseline maintenance asthma standard of care (SOC) treatment throughout the study.

    Biological: GSK3511294

  • Placebo comparator
    Placebo

    Participants received placebo SC injection once every 26 weeks (week 0 and week 26). Participants were to be maintained on their existing baseline maintenance asthma SOC treatment throughout the study.

    Biological: Placebo

Interventions

  • BiologicalGSK3511294

    GSK3511294 was administered using a pre-filled syringe.

    Also known as: Depemokimab

  • BiologicalPlacebo

    Placebo was administered as normal saline using a pre-filled syringe.

06

What researchers measure

Primary outcomes

  1. Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks

    Clinically significant exacerbations recorded were defined as worsening of asthma requiring the use of systemic corticosteroids (CS) \[such as intramuscular (IM), intravenous (IV) or oral\] and/or hospitalization and/or Emergency Department (ED) visit. For all participants, IV or oral steroids (e.g., prednisone) for at least 3 days or a single IM corticosteroid dose is required. For participants on maintenance systemic corticosteroids, at least double the existing maintenance dose for at least 3 days is required. Exacerbations recorded in the electronic case report form (eCRF) were considered as verified clinically significant exacerbations and included in the primary analysis. Exacerbations separated by less than 7 days was treated as a continuation of the same exacerbation.

    Time frame: Up to Week 52

Secondary outcomes

  1. Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score at Week 52

    The SGRQ is a 50-item patient-reported outcome tool used to measure Quality of Life in participants with airway obstruction diseases. The questions are designed to be self-completed by the participant. The total score was calculated by the symptom score, activity and impact score; and summarizing the impact of the disease on overall health status on 0-100 rating scale. Scores are expressed as a percentage of overall impairment where 100 representing worst possible health status and 0 indicating best possible health status. Higher scores indicating greater impairment of quality of life. Change from Baseline was defined as value at the indicated time point minus Baseline value.

    Time frame: Baseline (Day 1) and Week 52

  2. Change From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score at Week 52

    The ACQ-5 is a five-item questionnaire developed as a measure of participants asthma symptom control. The questions are designed to be self-completed by the participant. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, waking in the morning, activity limitation, shortness of breath and wheezing). The overall ACQ-5 response option is the mean score of all 5 questions representing 0 with no impairment/limitation and 6 as total impairment/ limitation. Higher scores indicated more limitations and lower score with better asthma control. Change from Baseline was defined as value at the indicated time point minus Baseline value.

    Time frame: Baseline (Day 1) and Week 52

  3. Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second (FEV1) At Week 52

    Forced Expiratory Volume in One Second (FEV1) is defined as the volume of air that can be forced out in one second after taking a deep breath by a person and will be measured by spirometry testing. Change from Baseline in clinic pre-bronchodilator FEV1 was determined. Change from Baseline was defined as value at the indicated time point minus Baseline value.

    Time frame: Baseline (Day 1) and Week 52

  4. Change From Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score at Week 52

    The ANSD is a 6-item self-administered patient reported diary developed by Patient Related Outcomes (PRO) Consortium's Asthma Working Group to facilitate comprehensive and reliable assessment of asthma symptoms from a participant's perspective. Participants were required to rate the severity of symptoms in 3 core categories: breathing symptoms (wheezing, shortness of breath), chest symptoms (chest tightness, chest pain) and cough. The ANSD was to be completed before going to bed and refers to asthma symptoms during the day. Symptoms are rated at their worst using an 11-point numeric rating scale ranging from 0 (None) to 10 (As bad as you can imagine). Higher scores indicate more severe symptoms. Mean daily scores of ANSD was calculated by weekly intervals. The baseline values were defined as the average score from Day -7 to Day -1 inclusive (at least 4 days must be non-missing). Change from Baseline was defined as value at each time point minus Baseline value.

    Time frame: Baseline to Week 52

  5. Change From Baseline in Asthma Daily Symptom Diary (ADSD) Weekly Mean Score at Week 52

    The ADSD is a 6-item self-administered patient reported diary developed by patient related outcomes (PRO) Consortium's Asthma Working Group to facilitate comprehensive and reliable assessment of asthma symptoms from a participant's perspective. Participants were required to rate the severity of symptoms in 3 core categories: breathing symptoms (wheezing, shortness of breath), chest symptoms (chest tightness, chest pain) and cough. The ADSD was to be completed upon waking and refers to asthma symptoms during the night-time. Symptoms are rated at their worst using an 11-point numeric rating scale ranging from 0 (None) to 10 (As bad as you can imagine). Higher scores indicate more severe symptoms. Mean daily scores of ADSD was calculated by weekly intervals. The baseline values were defined as the average score from Day -7 to Day -1 inclusive (at least 4 days must be non-missing). Change from Baseline was defined as value at each time point minus Baseline value.

    Time frame: Baseline to Week 52

  6. Annualized Rate of Exacerbations Requiring Hospitalization and/or Emergency Department (ED) Visit up to 52 Weeks

    Annualized Rate of exacerbations of asthma were defined as worsening of asthma which required use of systemic corticosteroids (CSs) and/or hospitalization and/or Emergency Department (ED) visit. For all participants, IV or oral steroids (e.g., prednisone) for at least 3 days or a single IM CS dose is required. For participants on maintenance systemic CSs, at least double the existing maintenance dose for at least 3 days is required. Exacerbations separated by less than 7 days will be treated as a continuation of the same exacerbation. Exacerbations Requiring Hospitalization and/or ED Visit are reported here.

    Time frame: Up to Week 52

07

Results

Posted Nov 29, 2024

Participant flow

A total of 397 participants were randomized to the study. Of which 380 participants were included in Full analysis set (FAS) population. FAS included all randomized participants who received at least 1 dose of study intervention excluding 12 participants from 2 sites with Good Clinical Practice (GCP) violation. Five (5) participants were randomized in error and did not receive any study drug.

Participant flow — Overall Study
MilestoneGSK3511294Placebo
Started263134
Full analysis population252128
Completed233117
Not completed3017
Withdrew: Adverse event11
Withdrew: Lack of efficacy41
Withdrew: Lost to follow-up22
Withdrew: Physician decision20
Withdrew: Pregnancy01
Withdrew: Withdrawal by subject106
Withdrew: Randomized, not treated41
Withdrew: Gcp violations75

Outcome measures

PrimaryAnnualized Rate of Clinically Significant Exacerbations up to 52 Weeks

Clinically significant exacerbations recorded were defined as worsening of asthma requiring the use of systemic corticosteroids (CS) \[such as intramuscular (IM), intravenous (IV) or oral\] and/or hospitalization and/or Emergency Department (ED) visit. For all participants, IV or oral steroids (e.g., prednisone) for at least 3 days or a single IM corticosteroid dose is required. For participants on maintenance systemic corticosteroids, at least double the existing maintenance dose for at least 3 days is required. Exacerbations recorded in the electronic case report form (eCRF) were considered as verified clinically significant exacerbations and included in the primary analysis. Exacerbations separated by less than 7 days was treated as a continuation of the same exacerbation.

Time frame:
Up to Week 52
Reported as:
Least squares mean · Exacerbation per participant per year
Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks
Exacerbation per participant per yearGSK3511294Placebo
Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks0.56 (0.44 to 0.70)1.08 (0.83 to 1.41)
Statistical analysis
  • GSK3511294 vs Placebo · Negative Binomial Distribution · p = <0.001 · Rate ratio: 0.52 · 95% CI 0.36 to 0.73
SecondaryChange From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score at Week 52

The SGRQ is a 50-item patient-reported outcome tool used to measure Quality of Life in participants with airway obstruction diseases. The questions are designed to be self-completed by the participant. The total score was calculated by the symptom score, activity and impact score; and summarizing the impact of the disease on overall health status on 0-100 rating scale. Scores are expressed as a percentage of overall impairment where 100 representing worst possible health status and 0 indicating best possible health status. Higher scores indicating greater impairment of quality of life. Change from Baseline was defined as value at the indicated time point minus Baseline value.

Time frame:
Baseline (Day 1) and Week 52
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score at Week 52
Scores on a scaleGSK3511294Placebo
Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score at Week 52-14.80 ± 1.041-12.49 ± 1.455
Statistical analysis
  • GSK3511294 vs Placebo · Mixed Models Repeated Measures (MMRM) · p = 0.200 · Least-square (ls) means: -2.31 · 95% CI -5.84 to 1.23
SecondaryChange From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score at Week 52

The ACQ-5 is a five-item questionnaire developed as a measure of participants asthma symptom control. The questions are designed to be self-completed by the participant. The 5 questions enquired to recall how their asthma had been during the previous week and to respond about the frequency and/or severity of symptoms (nocturnal awakening, waking in the morning, activity limitation, shortness of breath and wheezing). The overall ACQ-5 response option is the mean score of all 5 questions representing 0 with no impairment/limitation and 6 as total impairment/ limitation. Higher scores indicated more limitations and lower score with better asthma control. Change from Baseline was defined as value at the indicated time point minus Baseline value.

Time frame:
Baseline (Day 1) and Week 52
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score at Week 52
Scores on a scaleGSK3511294Placebo
Change From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score at Week 52-0.81 ± 0.065-0.70 ± 0.091
Statistical analysis
  • GSK3511294 vs Placebo · Mixed Models Repeated Measures (MMRM) · p = 0.333 · Difference in least-square mean: -0.11 · 95% CI -0.33 to 0.11
SecondaryChange From Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second (FEV1) At Week 52

Forced Expiratory Volume in One Second (FEV1) is defined as the volume of air that can be forced out in one second after taking a deep breath by a person and will be measured by spirometry testing. Change from Baseline in clinic pre-bronchodilator FEV1 was determined. Change from Baseline was defined as value at the indicated time point minus Baseline value.

Time frame:
Baseline (Day 1) and Week 52
Reported as:
Least squares mean · Liters (L)
Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second (FEV1) At Week 52
Liters (L)GSK3511294Placebo
Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in One Second (FEV1) At Week 520.240 ± 0.02860.184 ± 0.0407
Statistical analysis
  • GSK3511294 vs Placebo · Mixed Models Repeated Measures (MMRM) · p = 0.267 · Difference in least-square means: 0.056 · 95% CI -0.043 to 0.154
SecondaryChange From Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score at Week 52

The ANSD is a 6-item self-administered patient reported diary developed by Patient Related Outcomes (PRO) Consortium's Asthma Working Group to facilitate comprehensive and reliable assessment of asthma symptoms from a participant's perspective. Participants were required to rate the severity of symptoms in 3 core categories: breathing symptoms (wheezing, shortness of breath), chest symptoms (chest tightness, chest pain) and cough. The ANSD was to be completed before going to bed and refers to asthma symptoms during the day. Symptoms are rated at their worst using an 11-point numeric rating scale ranging from 0 (None) to 10 (As bad as you can imagine). Higher scores indicate more severe symptoms. Mean daily scores of ANSD was calculated by weekly intervals. The baseline values were defined as the average score from Day -7 to Day -1 inclusive (at least 4 days must be non-missing). Change from Baseline was defined as value at each time point minus Baseline value.

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score at Week 52
Scores on a scaleGSK3511294Placebo
Change From Baseline in Asthma Nighttime Symptom Diary (ANSD) Weekly Mean Score at Week 52-1.18 ± 0.091-0.97 ± 0.127
Statistical analysis
  • GSK3511294 vs Placebo · Mixed Models Repeated Measures (MMRM) · p = 0.173 · Difference in least square means: -0.21 · 95% CI -0.52 to 0.09
SecondaryChange From Baseline in Asthma Daily Symptom Diary (ADSD) Weekly Mean Score at Week 52

The ADSD is a 6-item self-administered patient reported diary developed by patient related outcomes (PRO) Consortium's Asthma Working Group to facilitate comprehensive and reliable assessment of asthma symptoms from a participant's perspective. Participants were required to rate the severity of symptoms in 3 core categories: breathing symptoms (wheezing, shortness of breath), chest symptoms (chest tightness, chest pain) and cough. The ADSD was to be completed upon waking and refers to asthma symptoms during the night-time. Symptoms are rated at their worst using an 11-point numeric rating scale ranging from 0 (None) to 10 (As bad as you can imagine). Higher scores indicate more severe symptoms. Mean daily scores of ADSD was calculated by weekly intervals. The baseline values were defined as the average score from Day -7 to Day -1 inclusive (at least 4 days must be non-missing). Change from Baseline was defined as value at each time point minus Baseline value.

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Asthma Daily Symptom Diary (ADSD) Weekly Mean Score at Week 52
Scores on a scaleGSK3511294Placebo
Change From Baseline in Asthma Daily Symptom Diary (ADSD) Weekly Mean Score at Week 52-1.13 ± 0.080-0.93 ± 0.112
Statistical analysis
  • GSK3511294 vs Placebo · Mixed Models Repeated Measures (MMRM) · p = 0.138 · Difference in least square means: -0.21 · 95% CI -0.48 to 0.07
SecondaryAnnualized Rate of Exacerbations Requiring Hospitalization and/or Emergency Department (ED) Visit up to 52 Weeks

Annualized Rate of exacerbations of asthma were defined as worsening of asthma which required use of systemic corticosteroids (CSs) and/or hospitalization and/or Emergency Department (ED) visit. For all participants, IV or oral steroids (e.g., prednisone) for at least 3 days or a single IM CS dose is required. For participants on maintenance systemic CSs, at least double the existing maintenance dose for at least 3 days is required. Exacerbations separated by less than 7 days will be treated as a continuation of the same exacerbation. Exacerbations Requiring Hospitalization and/or ED Visit are reported here.

Time frame:
Up to Week 52
Reported as:
Least squares mean · Exacerbation per participant per year
Annualized Rate of Exacerbations Requiring Hospitalization and/or Emergency Department (ED) Visit up to 52 Weeks
Exacerbation per participant per yearGSK3511294Placebo
Annualized Rate of Exacerbations Requiring Hospitalization and/or Emergency Department (ED) Visit up to 52 Weeks0.05 (0.02 to 0.09)0.11 (0.05 to 0.22)
Statistical analysis
  • GSK3511294 vs Placebo · Negative binomial distribution · p = 0.087 · Rate ratio: 0.42 · 95% CI 0.16 to 1.13

Adverse events

Collected over All-cause mortality, Serious adverse events (SAEs) and non-serious adverse events (Non-SAEs) were collected from the start of the study intervention (Day 1) till follow up week 56.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GSK35112940/251 (0%)19/251 (7.6%)138/251 (55%)
Placebo0/129 (0%)13/129 (10.1%)80/129 (62%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventGSK3511294Placebo
AsthmaRespiratory, thoracic and mediastinal disorders7/2516/129
PneumoniaInfections and infestations0/2512/129
Coronary artery diseaseCardiac disorders0/2511/129
PhimosisCongenital, familial and genetic disorders0/2511/129
Anaphylactic reactionImmune system disorders0/2511/129
SepsisInfections and infestations0/2511/129
SpondylolisthesisMusculoskeletal and connective tissue disorders0/2511/129
NephrolithiasisRenal and urinary disorders0/2511/129
UreterolithiasisRenal and urinary disorders0/2511/129
Benign prostatic hyperplasiaReproductive system and breast disorders0/2511/129
Most frequent other events
Showing 10 of 20
Most frequent other events
EventGSK3511294Placebo
NasopharyngitisInfections and infestations33/25127/129
COVID-19Infections and infestations36/25119/129
Upper respiratory tract infectionInfections and infestations21/2516/129
HeadacheNervous system disorders20/25110/129
BronchitisInfections and infestations12/25110/129
Rhinitis allergicRespiratory, thoracic and mediastinal disorders18/2513/129
InfluenzaInfections and infestations5/2519/129
ArthralgiaMusculoskeletal and connective tissue disorders14/2515/129
HypertensionVascular disorders6/2517/129
SinusitisInfections and infestations11/2516/129

Baseline characteristics

Full analysis set population included all randomized participants who received at least one dose of study intervention excluding participants from 2 sites with GCP violation. Participants were analyzed according to the intervention they were allocated at randomization.

Age, Continuous
Age, Continuous(YEARS)GSK3511294PlaceboTotal
Mean53.6 ± 16.0051.2 ± 16.5852.8 ± 16.22
Sex: Female, Male
Sex: Female, Male(Participants)GSK3511294PlaceboTotal
Female16081241
Male9247139
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GSK3511294PlaceboTotal
Asian522375
White18191272
Others191433
08

Study locations

129 sites
  • GSK Investigational Site
    Alabaster, Alabama 35007, United States
  • GSK Investigational Site
    Mobile, Alabama 36608, United States
  • GSK Investigational Site
    Phoenix, Arizona 85032, United States
  • GSK Investigational Site
    Beverly Hills, California 90048, United States
  • GSK Investigational Site
    Lancaster, California 93534, United States
  • GSK Investigational Site
    Colorado Springs, Colorado 80923, United States
  • GSK Investigational Site
    Lafayette, Colorado 80026, United States
  • GSK Investigational Site
    Aventura, Florida 33180, United States
  • GSK Investigational Site
    Hialeah, Florida 33014, United States
  • GSK Investigational Site
    Miami Lakes, Florida 33014, United States
  • GSK Investigational Site
    Miami, Florida 33144, United States
  • GSK Investigational Site
    Miami, Florida 33186, United States
  • GSK Investigational Site
    Orlando, Florida 32803, United States
  • GSK Investigational Site
    Atlanta, Georgia 30281, United States
  • GSK Investigational Site
    Evanston, Illinois 60026, United States
  • GSK Investigational Site
    Columbia, Maryland 21044, United States
  • GSK Investigational Site
    Dearborn, Michigan 48124, United States
  • GSK Investigational Site
    Ypsilanti, Michigan 48197, United States
  • GSK Investigational Site
    Saint Louis, Missouri 63110, United States
  • GSK Investigational Site
    Northfield, New Jersey 08225, United States
  • GSK Investigational Site
    Toms River, New Jersey 08755, United States
  • GSK Investigational Site
    Bronx, New York 10467, United States
  • GSK Investigational Site
    Huntersville, North Carolina 28078, United States
  • GSK Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45229, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45231, United States
  • GSK Investigational Site
    Edmond, Oklahoma 73034, United States
  • GSK Investigational Site
    Altoona, Pennsylvania 16601, United States
  • GSK Investigational Site
    DuBois, Pennsylvania 15801, United States
  • GSK Investigational Site
    Hershey, Pennsylvania 17033, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19140, United States
  • GSK Investigational Site
    Rapid City, South Dakota 57702, United States
  • GSK Investigational Site
    Allen, Texas 75013, United States
  • GSK Investigational Site
    Boerne, Texas 78006, United States
  • GSK Investigational Site
    Dallas, Texas 75225, United States
  • GSK Investigational Site
    Houston, Texas 77084, United States
  • GSK Investigational Site
    San Antonio, Texas 78207, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    San Antonio, Texas 78258, United States
  • GSK Investigational Site
    Bellingham, Washington 98225, United States
  • GSK Investigational Site
    Milwaukee, Wisconsin 53226, United States
  • GSK Investigational Site
    Coffs Harbour, New South Wales 2450, Australia
  • GSK Investigational Site
    South Brisbane, Queensland 4101, Australia
  • GSK Investigational Site
    Sherwood Park, Alberta T8H 0N2, Canada
  • GSK Investigational Site
    Kamloops, British Columbia V1Y 4N7, Canada
  • GSK Investigational Site
    Burlington, Ontario L7N 3V2, Canada
  • GSK Investigational Site
    Quebec City, Quebec G1V 4W2, Canada
  • GSK Investigational Site
    Windsor, 5000, Canada
  • GSK Investigational Site
    Jindrichuv Hradec, 377 01, Czechia
  • GSK Investigational Site
    Tabor, 390 02, Czechia
  • GSK Investigational Site
    Teplice, 415 01, Czechia
  • GSK Investigational Site
    Annecy Cedex, 74011, France
  • GSK Investigational Site
    Caen cedex 9, 14033, France
  • GSK Investigational Site
    Cannes, 06414, France
  • GSK Investigational Site
    Marseille, 13015, France
  • GSK Investigational Site
    Paris, 75014, France
  • GSK Investigational Site
    Strasbourg, 67091, France
  • GSK Investigational Site
    GOdOll?, 2100, Hungary
  • GSK Investigational Site
    Mosonmagyarovar, 9200, Hungary
  • GSK Investigational Site
    Szigetvar, 7900, Hungary
  • GSK Investigational Site
    Brescia, 25123, Italy
  • GSK Investigational Site
    Foggia, 71122, Italy
  • GSK Investigational Site
    Messina, 98124, Italy
  • GSK Investigational Site
    Monserrato CA, 09042, Italy
  • GSK Investigational Site
    Palermo, 90127, Italy
  • GSK Investigational Site
    Pietra Ligure SV, 17027, Italy
  • GSK Investigational Site
    Rozzano MI, 20089, Italy
  • GSK Investigational Site
    Salerno, 84131, Italy
  • GSK Investigational Site
    Siena, 53100, Italy
  • GSK Investigational Site
    Tradate VA, 21100, Italy
  • GSK Investigational Site
    Aichi, 470-1192, Japan
  • GSK Investigational Site
    Aichi, 489-8642, Japan
  • GSK Investigational Site
    Chiba, 275-8580, Japan
  • GSK Investigational Site
    Ehime, 790-0024, Japan
  • GSK Investigational Site
    Fukui, 910-8526, Japan
  • GSK Investigational Site
    Fukuoka, 802-0052, Japan
  • GSK Investigational Site
    Fukuoka, 805-8508, Japan
  • GSK Investigational Site
    Fukuoka, 811-1394, Japan
  • GSK Investigational Site
    Fukuoka, 813-0017, Japan
  • GSK Investigational Site
    Fukushima, 960-1295, Japan
  • GSK Investigational Site
    Hiroshima, 734-8530, Japan
  • GSK Investigational Site
    Hokkaido, 053-8506, Japan
  • GSK Investigational Site
    Hokkaido, 064-0804, Japan
  • GSK Investigational Site
    Hyogo, 653-0013, Japan
  • GSK Investigational Site
    Hyogo, 670-0849, Japan
  • GSK Investigational Site
    Kagawa, 761-8073, Japan
  • GSK Investigational Site
    Kagawa, 762-8550, Japan
  • GSK Investigational Site
    Kagoshima, 890-8520, Japan
  • GSK Investigational Site
    Kanagawa, 231-8682, Japan
  • GSK Investigational Site
    Kanagawa, 232-0024, Japan
  • GSK Investigational Site
    Niigata, 951-8520, Japan
  • GSK Investigational Site
    Okayama, 702-8055, Japan
  • GSK Investigational Site
    Saga, 843-0393, Japan
  • GSK Investigational Site
    Shizuoka, 420-8527, Japan
  • GSK Investigational Site
    Tokyo, 103-0027, Japan
  • GSK Investigational Site
    Tokyo, 141-8625, Japan
  • GSK Investigational Site
    Tokyo, 142-8666, Japan
  • GSK Investigational Site
    Tokyo, 158-0097, Japan
  • GSK Investigational Site
    Tokyo, 185-0014, Japan
  • GSK Investigational Site
    Tokyo, 204-8585, Japan

Showing the first 100 of 129 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Jackson DJ, Wechsler ME, Jackson DJ, Bernstein D, Korn S, Pfeffer PE, Chen R, Saito J, de Luiz Martinez G, Dymek L, Jacques L, Bird N, Schalkwijk S, Smith D, Howarth P, Pavord ID; SWIFT-1 and SWIFT-2 Investigators; SWIFT-1 Investigators; SWIFT-2 Investigators. Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype. N Engl J Med. 2024 Dec 19;391(24):2337-2349. doi: 10.1056/NEJMoa2406673. Epub 2024 Sep 9. PubMed 39248309 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Apr 2024, 38 months.

Results were first posted in Nov 2024, 7 months after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 38 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2021
First posted
Jan 22, 2021
StartActual
Feb 4, 2021
Primary completionActual
Apr 11, 2024
CompletionActual
Apr 11, 2024
Results first posted
Nov 29, 2024
Last update
Nov 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04718103
Lead sponsor
GlaxoSmithKline
Collaborators
Iqvia Pty Ltd
Responsible party
Sponsor
First posted
Jan 22, 2021
Start date
Feb 4, 2021
Primary completion
Apr 11, 2024
Completion
Apr 11, 2024
Results posted
Nov 29, 2024
Last update
Nov 29, 2024

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Depemokimab

Start the discussion